Abstract No. 4 ▪ ABSTRACT OF THE YEAR Radioembolization with yttrium-90 glass microspheres as first-line treatment for unresectable intrahepatic cholangiocarcinoma: a prospective phase 2 clinical trial

Abstract

For patients with unresectable intrahepatic cholangiocarcinoma (IHC), the current standard of care first-line treatment is gemcitabine with cisplatin, based on the ABC-02 trial which demonstrated a median OS of 11.7 months. This therapy is complicated by severe (grade 3-4) adverse events in 70% of patients. A recent phase 2 trial demonstrated 22 months median OS when cisplatin-gemcitabine chemotherapy was used with concomitant radioembolization as first line treatment, but 71% of patients had grades 3-4 toxicities, which were mostly related to the chemotherapy. The purpose of our trial was to evaluate the safety and efficacy of yttrium-90 (Y-90) glass microsphere radioembolization as first-line treatment without chemotherapy for unresectable IHC.